Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-12-12
2006-12-12
Campell, Bruce R. (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387500, C530S388100, C530S388200, C530S388230, C530S350000, C530S389100
Reexamination Certificate
active
07148329
ABSTRACT:
The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of auto-immune diseases, the treatment of allergy, and/or for inhibiting HIV infection. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies, and to a method for isolating dendritic cells using such antibodies.
REFERENCES:
patent: W/O 93/01820 (1993-02-01), None
patent: W/O 96/23882 (1996-08-01), None
patent: W/O 98/02456 (1998-01-01), None
patent: W/O 98/28332 (1998-07-01), None
patent: W/O 98/41633 (1998-09-01), None
patent: W/O 98/49306 (1998-11-01), None
patent: WO 96/55508 (1998-12-01), None
patent: WO 98/55508 (1998-12-01), None
Curtis et al. PNAS, 1992, 89 :8356-8360.
Curtis PNAS 1992, vol. 89, pp. 8356-8360.
Sequence Comparison sheet of Curtis vs application SEQ ID#2.
Curtis PNAS 1992, vol. 89, pp. 8356-8360.
Sequence Comparison sheet of Curtis vs application SEQ ID#2.
Harlow and Lane, Antibodies, A Laboratory Manual.
Gaijtenbeek, et al., Identification of Different Binding Sites in the Dendritic Cell-specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1 J. Biol. Chem. 277: 11314-11320.
Knight SC and Patterson S, “Bone Marrow-Derived Dendritic Cells, Infection with Human Immunodeficiency Virus, and Immunopathology”, Annu. Rev. Immunol. 15:593-615 (1997).
Zoeteweij JP and Blauvelt A, “HIV-Dendritic Cell Interactions Promote Efficient Viral Infection of T Cells”, J. Biomed. Sci. 5:253-259 (1998).
Tsunetsugu-Yokota Y et al., “Efficient Virus Transmision from Dendritic Cells to CD4+T Cells in Response to Antigen Depends on Close Contact through Adhesion Molecules”, Virology 239:259-268 (1997).
Manca F et al., “Dendritic Cells are Potent Antigen-Presenting Cells for un Vitro Induction of Primary Human CD4+T-Cell Lines Specific for HIV gp120”, Journal of Acquired Immune Deficiency Syndromes 7:15-23 (1994).
Curtis BM et al., “Sequence and Expression of a Membrane-Associated C-type Lectin that Exhibits CD4-Independent Binding of Human Immunodeficiency Virus Envelope Glycoprotein gp120”, Proc. Natl. Acad. Sci. USA 89:8356-8360 (1992).
GENBANK Accession No. AB015629 including revisions updated on Apr. 17, 1999, Apr. 20, 1999, Apr. 20, 1999 (later time); Jul. 26, 2001; and Jul. 23, 2002.
Andre et al., Journal of Virology, 72(2), pp. 1497-1503 (1998).
Biosis Database, Prev 197866028654 & Kataoka et., Cancer Research, 38(5), pp. 1202-1207 (1987).
Toda, et al., Immunology, 92, pp. 111-117 (1997).
Figdor Carl Gustav
Geijtenbeek Teunis Bernard Herman
Kooyk Yvette Van
Torensma Ruurd
Campell Bruce R.
Fish & Neave IP Group Ropes & Gray LLP
Hill Myron C.
Katholieke Universiteit Nijmegen
LandOfFree
Composition and method for modulating dendritic cell-t cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for modulating dendritic cell-t cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for modulating dendritic cell-t cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3671973